About Us

Since 1995 Vybion innovations have met significant needs in the recombinant protein development market. Milestones include:

  • Developed more than 100 recombinant proteins for therapeutic and diagnostic applications,
  • ProCode™ Technologies, a proprietary proteomics platform

Ongoing research at Vybion brings continually advancing capabilities to our clients.

  • Collaboration with Cornell University provides a wide range of capabilities
  • NIH-funded research to enhance gene expression through transcriptional enhancement

Contract Biopharmaceutical Development

Contract biopharmaceutical development is an important strategic thrust of our business.

  • Optimized genes cloned and expressed in several systems
  • Early stage bioprocess development
  • Fermentation, process optimization, and scale up through clinical manufacturing
  • Clients include major pharmaceutical companies, virtual and startup companies

Significant Innovations